For H-FABP to be used as an early marker in detection of myocardial injury, the assay must have a fast turnaround time. Several biochemical assays of H-FABP have been described; however, these assays are of limited use for routine clinical practice because they are not automated. The sandwich immunoassay used in this study is a rapid and totally automated assay suitable for clinical use.
Because H-FABP appears early in the blood after myocardial damage, we were particularly interested in its diagnostic performance during the first 4 h. Our data show that although H-FABP has a somewhat better diagnostic performance than myoglobin, it did not demon-strate the sensitivity and specificity necessary to detect AMI significantly earlier than do the existing markers.
To make a meaningful difference in early detection of AMI, new cardiac biomarkers will need a higher sensitivity during the first 1-2 h after chest pain. Patients detected very early may have evidence of plaque rupture and reduced coronary artery blood flow, but may be detected substantially before the onset of irreversible damage that is characterized by release of enzymes and proteins. Tests that indicate the presence of inflammation, thrombus formation, platelet aggregation, and reversible ischemia are possible candidates for early markers for AMI (10 ) .
The conventional laboratory test for diagnosing iron deficiency anemia (IDA) is the measurement of serum ferritin. In healthy persons, serum ferritin is directly proportional to body iron stores. In the presence of anemia, a value Ͻ20 g/L is regarded as evidence of IDA (1 ) . In patients with anemia of chronic disease (ACD), an increase in serum ferritin, unrelated to iron storage status, occurs. Serum ferritin concentrations usually exceed 100 g/L when iron stores are adequate, but they may still be within the reference interval in the presence of coexisting iron deficiency (1 ) . The assay lacks sensitivity in diagnosing IDA in patients with ACD, as well as in patients with acute infections and with liver diseases.
The best established method for evaluating iron stores is examination of bone marrow iron, but this test is cumbersome and expensive.
Since the early 1970s, measurement of the zinc protoporphyrin concentration (ZPP) in erythrocytes has been used as test for iron deficiency. When there is insufficient iron for incorporation into protoporphyrin IX to form heme, ZPP increases, indicating iron-deficient erythropoiesis (2 ) . Most authors have reported a high sensitivity in diagnosing IDA, irrespective of the presence of complicating diseases (3) (4) (5) . However, disturbed incorporation of iron into protoporphyrin IX can also occur in other diseases, such as ACD, hemolytic anemias, bone marrow diseases, and lead intoxication. The specificity of ZPP in diagnosing IDA is limited (6, 7 ) .
In recent years, the measurement of soluble transferrin receptor (sTfR) fragments has been introduced for the identification of iron deficiency (8 ) . The concentration of sTfR is directly proportional to the number of red cell precursors. An exception to this rule is in patients with IDA. A reduction in iron supply leads to up-regulation of transferrin receptor synthesis, producing an increase in sTfR concentration. Several authors have reported a good sensitivity in diagnosing IDA in patients without complicating diseases (9 -12 ) . However, the specificity of the test is negatively influenced by the fact that in cases of increased erythropoietic activity and in cases of disturbed iron transport to and in the cells, the sTfR concentration can also be increased (9, 10, 13 ) .
ZPP measurements have been included in the anemia investigation protocol of our laboratory for several years. In this study, we also performed sTfR measurements and compared the results with ZPP.
In 232 adult patients (171 women, 61 men) referred for investigation of anemia, hemoglobin (Hb), mean corpuscular volume (MCV), reticulocyte count, ZPP, serum ferritin, and sTfR were measured. In patients with reticulocyte counts Ͼ25‰, haptoglobin was determined, and in patients with MCV Ͼ100 fL, vitamin B 12 and folic acid concentrations were measured. Anemia was defined as Hb Ͻ137 g/L in men and Ͻ121 g/L in women. Hb, MCV, and ZPP measurements were performed in peripheral blood in EDTA. Hb and MCV were measured with an automated cell counter (NE 8000; Sysmex). ZPP concentrations were determined with a front-face hematofluorometer (AVIV Biomedical). To avoid the influence of plasma components, the erythrocytes were washed before ZPP was measured. ZPP measured as the ZPP/Hb ratio is expressed in mol/mol heme. The reference interval for ZPP in our hospital is 15-55 mol/mol heme (mean Ϯ 2 SD). sTfR assays were performed in plasma, using a kit based on a polyclonal antibody in a sandwich immunoassay (Eurogenetics). To find the reference values, plasma samples of 70 healthy adult volunteers were analyzed. We found reference values of 310 -745 kilounits/L (mean Ϯ 2 SD). Serum ferritin measurements were performed using an enzyme-linked assay (IMx; Abbott). Linear regression analysis was performed using commercial software (SPPS).
We found decreased haptoglobin concentrations in three patients, indicating hemolysis. They showed increased sTfR concentrations, and two of these patients had increased ZPP. In seven patients, MCV was Ͼ100 fL. None of these patients showed decreased vitamin B 12 or folic acid concentrations.
We divided the patients into four groups, according to serum ferritin concentrations. Table 1 shows the number of patients with normal and increased ZPP and sTfR concentrations in the four groups.
Using a definition of IDA as anemia in combination with a serum ferritin concentration Ͻ20 g/L, we found sensitivities for ZPP and sTfR in diagnosing IDA of 81% and 78%, respectively. When we assumed that patients with serum ferritin concentrations Ͼ100 g/L did not suffer from IDA, the specificities of ZPP and sTfR in diagnosing IDA were 59% and 77%, respectively. Similar specificities were found when we took serum ferritin concentrations Ͼ200 g/L as evidence of anemia not caused by iron deficiency (57% for ZPP and 76% for sTfR).
In Fig. 1A , sTfR is plotted against ZPP in patients with serum ferritin concentrations Ͻ20 g/L. A linear correlation (r ϭ 0.89; P Ͻ0.001) was found. In Fig. 1B , ZPP and sTfR are plotted against MCV in patients with serum ferritin concentrations Ͻ20 g/L. A linear correlation between MCV and ZPP (r ϭ Ϫ0.75; P Ͻ0.001) as well as MCV and sTfR (r ϭ Ϫ0.72; P Ͻ0.001) was found. Like- 
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Technical Briefs wise, a linear correlation between Hb and ZPP (r ϭ Ϫ0.71; P Ͻ0.001) as well as between Hb and sTfR (r ϭ Ϫ0.70; P Ͻ0.001) was found in patients with serum ferritin values Ͻ20 g/L (data not shown).
The linear correlation between ZPP and sTfR concentrations in the patients with serum ferritin values Ͻ20 g/L indicates that both markers reflect the severity of iron-deficient erythropoiesis in a similar way in IDA.
Ten of the 86 patients with serum ferritin concentrations Ͻ20 g/L showed both sTfR and ZPP concentrations within the reference values. None of these patients showed microcytosis. It is likely that in these iron-depleted patients, anemia was not caused by iron deficiency but by other factors, such as acute bleeding or hemodilution in pregnancy. When we excluded these patients, the sensitivities of ZPP and sTfR in diagnosing IDA increased to 92% and 88%, respectively. Nine patients with serum ferritin concentrations Ͻ20 g/L and mild anemia showed increased ZPP concentrations (mean, 70 mol/ mol heme; range, 58 -105 mol/mol heme) with sTfR concentrations within the reference values. In IDA, the decrease in Hb concentration is caused by diminished erythropoietic activity and impaired hemoglobinization of the cells. The sTfR concentration in IDA is the net effect of the decrease in erythropoietic activity and the increase in density of surface transferrin receptors on the erythropoietic cells. Especially in patients with low erythropoietic activity and mild iron-deficient erythropoiesis, sTfR concentrations may not rise to abnormal concentrations. Six mildly anemic patients with serum ferritin concentrations Ͻ20 g/L showed increased sTfR concentrations (mean, 875 kilounits/L; range, 752-1039 kilounits/L) without increased ZPP (mean, 45 mol/mol heme). Because ZPP is fixed in circulating erythrocytes, its concentration in whole blood will change only when new erythrocytes enter the circulation. The ZPP concentration in the erythrocytes reflects the severity of iron deficiency of the erythropoietic cells during the prior 3 months; therefore, ZPP concentrations may be within the reference interval in recently developed IDA. The ZPP and sTfR results in the individual patient might give insight into the development of IDA for that particular patient.
In earlier studies, we found a sensitivity of 95% for ZPP in diagnosing IDA. Other authors have reported similar results (4, 5 ) . For sTfR, a sensitivity of 90% has been reported (11, 12 ) . In this study, we found a lower sensitivity for both markers. This may reflect the fact that some patients with severe IDA were not included in this study because some physicians did not request an anemia investigation according to the laboratory protocol for such patients.
Taking a serum ferritin concentration Ͼ100 g/L as cutoff value for excluding IDA, the specificity in diagnosing IDA was 77% for sTfR and 59% for ZPP, and similar values were found for serum ferritin concentrations Ͼ200 g/L. The low specificities of both tests render them insufficient to be used as a single test for identification of iron deficiency in unselected patients, as was reported by others (14 -16 ) . Table 1 , 18 of the 31 patients with serum ferritin concentrations Ͼ100 g/L and 11 of the 30 patients with serum ferritin concentrations of 20 -100 g/L showed increased ZPP with normal sTfR concentrations, indicating that iron-deficient erythropoiesis in these patients did not cause increased transferrin receptor synthesis. In patients with ACD, an impaired ability to respond to erythropoietin, blunted erythropoiesis, and decreased transferrin receptor expression may cause low sTfR concentrations (17 ) . The sensitivity of sTfR in diagnosing concomitant IDA in such patients may be negatively influenced by these phenomena. Indeed, in patients with ACD and concomitant iron deficiency, mean sTfR concentrations tend to be lower than in patients with uncomplicated IDA (12, 18 ) . More studies should be performed to assess the sensitivity of sTfR in diagnosing IDA in patients with concomitant diseases. If the sensitivity is as good as in patients with uncomplicated IDA, it might be useful to perform this test in patients in whom ZPP and serum ferritin concentrations are inconclusive. In patients with sTfR concentrations within the reference interval, examination of bone marrow iron then can be omitted. Apolipoprotein (apo) E is a M r 34 000 plasma protein involved in lipid metabolism (1 ) and is genetically polymorphic. There are three common codominant alleles, designated ⑀2, ⑀3, and ⑀4 (2) . The genetic basis of the common alleles lies within codons 112 and 158 of the gene that codes for the 299-amino acid protein (3 ) . At these two sites (112/158), ⑀2, ⑀3, and ⑀4 alleles contain TGC/TGC (Cys/Cys), TGC/CGC (Cys/Arg), and CGC/CGC (Arg/ Arg), respectively. The apo ⑀3 allele is the predominant isoform in all populations studied to date. The apo ⑀4 allele is associated with increased total serum cholesterol and greater risk for coronary heart disease (4 ) ; it also constitutes a major risk factor for Alzheimer disease (5 ) . The apo ⑀2 allele seems to have a protective effect against Alzheimer disease and is associated with longevity (6 ). However, most patients with familial hyperlipoproteinemia type III are homozygous for the ⑀2 allele (7 ) . Thus, interest in apo E genotyping is high, both on the basis of epidemiological research and for the purpose of diagnosing dyslipidemia or dementia.
As shown in
The three common apo E alleles lead to six common phenotypes originally disclosed by isoelectric focusing and immunoblotting (7 ) . However, with this methodology, different degrees of protein posttranslational modification may give rise to misleading results, particularly in pathological states (8 ) . These ambiguities can be circumvented by the use of genotyping methods such as allelespecific oligonucleotide hybridization (9 ) , restriction enzyme analysis (ASRA) (10, 11 ) , the amplification refractory mutation system (12 ) , oligonucleotide ligation assay (13 ) , heteroduplex analysis (14 ), or single-strand conformation polymorphism (15 ) . Such systems generally are time-consuming and difficult to automate because they require postamplification procedures such as restriction enzyme digestion and/or electrophoresis. Of these methods, the ASRA procedure has been most widely adopted, although it has some drawbacks for large-scale DNA diagnosis, particularly related to the complex electrophoretic pattern that results from partial enzymatic digestion (16 ) .
In this report, we describe the clinical evaluation of a commercially available DNA assay for apo E genotyping that uses rapid-cycle PCR and fluorescence resonance energy transfer (FRET) with the LightCycler (17 ) . To allow simultaneous analysis of the two polymorphic codons in a single reaction, two reporter dyes with different excitation and emission spectra, LightCycler-Red 640 (LC-Red 640) and LC-Red 705, were used, with color compensation software to correct for the temperaturedependent crossover (crosstalk) between the emission spectra of the dyes.
In the assay, a 265-bp fragment harboring exon 4 of the apo E gene is amplified from human genomic DNA. The detection probes covering codons 112 and 158 are 5Ј labeled with LC-Red 640 and LC-Red 705, respectively. The corresponding anchor probes are fluorescein-labeled at their 3Ј ends. When a pair of hybridization probes hybridizes to the same strand internal to the unlabeled PCR primers, the probes come in close proximity, producing FRET. During FRET, the acceptor fluorophores LC-Red 640 and LC-Red 705 emit fluorescence, which is measured in exact temporal coincidence in channels 2 and 3, respectively, of the optical system of the LightCycler, using a linear arrangement of dichroic bandpass filters (17 ) .
Because the intensity of the FRET signal depends on the amount of specific PCR product generated, this detection strategy allows monitoring of the amplification process on a per-cycle basis. More importantly, homogeneous genotyping is achieved by analysis of the melting behavior of
